CPIC Guidelines and Evidence Levels

The Clinical Pharmacogenetics Implementation Consortium (CPIC) is an international body that translates established gene-drug associations into peer-reviewed clinical guidance. Rather than asking whether a gene affects a drug, CPIC guidelines assume the test result is available and describe how an established genotype should inform prescribing. CPIC also grades gene-drug pairs by evidence and assigns guideline recommendations a strength, helping users judge how confidently a pairing can be acted upon.

Definition

CPIC guidelines are peer-reviewed, freely available pharmacogenomic prescribing guidelines that translate an established genotype into a predicted phenotype and clinical guidance, accompanied by an evidence-level grading of gene-drug pairs and a strength rating for each recommendation.

Scope

This entry describes what CPIC is, how its guidelines are framed, and how its evidence-grading and recommendation-strength systems work. It situates CPIC alongside the parallel Dutch Pharmacogenetics Working Group framework. It is a reference description of an evidence framework and does not reproduce any specific drug recommendation or dosing instruction.

Core questions

• What question do CPIC guidelines answer, and what do they deliberately leave out?
• How does CPIC grade the evidence behind a gene-drug pair?
• What does the strength of a recommendation mean?
• How does CPIC relate to other frameworks such as the Dutch Pharmacogenetics Working Group?

Key concepts

• Established genotype assumption
• Gene-drug pair evidence levels
• Strength of recommendation
• Genotype-to-phenotype translation tables
• Actionable gene-drug pairs
• Dutch Pharmacogenetics Working Group as a parallel framework

Mechanisms

CPIC was created to remove a specific barrier to implementation: clinicians may have a genotype result but no clear guidance on how to use it. CPIC guidelines therefore start from the assumption that a genetic test result is already available and focus on translating that result into a phenotype and a prescribing recommendation (Relling & Klein, 2011). Each gene-drug pair is assigned an evidence level reflecting the strength of the underlying literature, and each individual recommendation is rated for strength, so users can distinguish well-supported guidance from weaker suggestions (Relling et al., 2019). Guidelines are published openly and updated as evidence accrues. A parallel European framework, the Dutch Pharmacogenetics Working Group, issues its own recommendations that broadly align with CPIC but differ in method and occasionally in conclusions (Bank et al., 2017).

Clinical relevance

CPIC's evidence levels and recommendation strengths give readers a structured way to gauge how robustly a gene-drug relationship is supported before any clinical use is considered. This entry explains the framework so that pharmacogenomic guidance can be appraised critically; it does not restate or endorse any particular prescribing or dosing recommendation, which remain matters for qualified clinicians applying current guidelines.

Evidence & guidelines

CPIC itself is the central evidence-and-guideline framework described here: it grades gene-drug evidence and rates recommendation strength, publishing guidelines that are peer-reviewed and freely accessible (Relling & Klein, 2011; Relling et al., 2019). Comparative analyses show substantial concordance, with some differences, between CPIC and the Dutch Pharmacogenetics Working Group (Bank et al., 2017). These frameworks define how evidence is organized and are not themselves individualized clinical advice.

History

CPIC was established in 2009 as a partnership between the Pharmacogenomics Knowledge Base and the Pharmacogenomics Research Network to address the gap between knowing a gene-drug association and acting on a test result. Its early publications set out the consortium's purpose and the structure of its guidelines (Relling & Klein, 2011). Over the following decade CPIC refined its evidence-grading and recommendation-strength systems and expanded its catalogue of gene-drug pairs, becoming a reference standard for pharmacogenomic implementation worldwide (Relling et al., 2019; Roden, 2019).

Debates

Harmonizing CPIC and Dutch Pharmacogenetics Working Group guidance

CPIC and the Dutch Pharmacogenetics Working Group use different methods and occasionally reach different recommendations for the same gene-drug pair, prompting ongoing efforts to compare and harmonize the two frameworks.

Key figures

• Mary V. Relling
• Teri E. Klein
• Kelly E. Caudle
• Henk-Jan Guchelaar

Seminal works

• relling-2011
• relling-2019
• bank-2017

Frequently asked questions

Does CPIC decide whether a patient should be tested?

No. CPIC guidelines assume a test result is already available and focus on how to interpret and act on an established genotype; they do not by themselves direct whether testing should be ordered.

What does a recommendation's strength tell me?

It signals how confident the guideline authors are in the advice given the underlying evidence, helping users distinguish strongly supported recommendations from weaker or optional ones.